Key facts
- This page summarizes Inscobee Inc.'s Form 4 filing for Apimeds Pharmaceuticals US, Inc. (APUS).
- 7 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 14 May 2025, 17:52.
Inscobee Inc. - 12 May 2025 Form 4 Insider Report for Apimeds Pharmaceuticals US, Inc. (APUS)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- APUS
- Reported as of
- 12 May 2025
- Net transaction value
- +$2,000,001
- SEC form
- 4
- Accepted by SEC
- 14 May 2025, 17:52:52 UTC
- Prior SEC filing
- 14 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Inscobee Inc. filed Form 4 for Apimeds Pharmaceuticals US, Inc. (APUS) on 14 May 2025.
Change
- Previous filing in this sequence was filed on 14 May 2025.
- Current net transaction value: +$2,000,001.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002057997
Primary reporting owner
Inscobee Inc.
- Relationship
- 10%+ Owner
- Address
- ROOM 613, DIGITAL-RO 130, 6F, GEUMCHEON-GU, SEOUL, KOREA, REPUBLIC OF
- Signature
- /s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact
- Signature date
- 14 May 2025
This filing has been restated.
Open the amended filing.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
APUS
transaction
Common Stock, par value $0.01 per share
Purchase
- Transaction value
- $2,000,000
- Shares
- +500,000
- Change %
- +34%
- Price
- $4.00
- Shares after
- 1,984,616
- Date
- 12 May 2025
- Ownership
- Direct
APUS
transaction
Common Stock, par value $0.01 per share
Conversion of derivative security
- Transaction value
- $473,205
- Shares
- +182,002
- Change %
- +4.4%
- Price
- $2.60
- Shares after
- 4,316,618
- Date
- 12 May 2025
- Ownership
- By Apimeds Inc.
- Footnotes
- F1, F2, F3
APUS
transaction
Common Stock, par value $0.01 per share
Conversion of derivative security
- Transaction value
- $184,834
- Shares
- +71,090
- Change %
- +1.6%
- Price
- $2.60
- Shares after
- 4,387,708
- Date
- 12 May 2025
- Ownership
- By Apimeds Inc.
- Footnotes
- F2, F3, F4
APUS
transaction
Common Stock, par value $0.01 per share
Conversion of derivative security
- Transaction value
- $114,507
- Shares
- +44,041
- Change %
- +2.2%
- Price
- $2.60
- Shares after
- 2,028,657
- Date
- 12 May 2025
- Ownership
- Direct
- Footnotes
- F2, F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
APUS
transaction
Derivative
Convertible Promissory Note
Conversion of derivative security
- Transaction value
- $473,205
- Shares
- Change %
- Price
- Shares after
- 0
- Date
- 12 May 2025
- Ownership
- By Apimeds Inc.
- Underlying class
- Common Stock, par value $0.01 per share
- Underlying amount
- 182,022
- Exercise price
- $2.60
- Footnotes
- F1, F2, F3
APUS
transaction
Derivative
Convertible Promissory Note
Conversion of derivative security
- Transaction value
- $184,833
- Shares
- Change %
- Price
- Shares after
- 0
- Date
- 12 May 2025
- Ownership
- By Apimeds Inc.
- Underlying class
- Common Stock, par value $0.01 per share
- Underlying amount
- 71,090
- Exercise price
- $2.60
- Footnotes
- F2, F3, F4
APUS
transaction
Derivative
Convertible Promissory Note
Conversion of derivative security
- Transaction value
- $114,507
- Shares
- Change %
- Price
- Shares after
- 0
- Date
- 12 May 2025
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.01 per share
- Underlying amount
- 44,041
- Exercise price
- $2.60
- Footnotes
- F2, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
On August 30, 2021, Apimeds Pharmaceuticals US, Inc. (the "Issuer") issued to Apimeds Inc. ("Apimeds Korea") a convertible promissory note in the principal amount of $400,000 (as amended, the "August 2021 Note"). All outstanding principal and accrued and unpaid interest owed under the August 2021 Note is due and payable on the earlier of (i) December 31, 2026, or (ii) the consummation of an offering of the Issuer's common stock resulting in the listing of the Issuer's common stock on the NYSE American, or other national securities exchange (a "Qualified Offering"). The August 2021 Note bears interest at an annual rate of 5%. The August 2021 Note is convertible into shares of common stock at a conversion price of $2.60 per share (the "Conversion Price"). The amount reported in Column 3 of Table II represents the original principal amount of $400,000, plus $73,205 of accrued and unpaid interest.
Footnote F2
On May 12, 2025, the Issuer completed a Qualified Financing and all outstanding principal and accrued and unpaid interest owed under the note converted into common stock at the Conversion Price.
Footnote F3
The shares of common stock are owned directly by Apimeds Korea, which is a wholly owned subsidiary of the reporting person. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Footnote F4
On March 21, 2022, the Issuer issued to Apimeds Korea a convertible promissory note in the principal amount of $160,000 (as amended, the "March 2022 Note"). All outstanding principal and accrued and unpaid interest owed under the March 2022 Note is due and payable on the earlier of (i) December 31, 2026, or (ii) the consummation of a Qualified Offering. The March 2022 Note bears interest at an annual rate of 5%. The March 2022 Note is convertible into shares of common stock at the Conversion Price. The amount reported in Column 3 of Table II represents the original principal amount of $160,000, plus $24,833 of accrued and unpaid interest.
Footnote F5
On June 3, 2022, the Issuer issued to Inscobee Inc. a convertible promissory note in the principal amount of $100,000 (as amended, the "June 2022 Note"). All outstanding principal and accrued and unpaid interest owed under the June 2022 Note is due and payable on the earlier of (i) December 31, 2026, or (ii) the consummation of a Qualified Offering. The June 2022 Note bears interest at an annual rate of 5%. The June 2022 Note is convertible into shares of common stock at the Conversion Price. The amount reported in Column 3 of Table II represents the original principal amount of $100,000, plus $14,507 of accrued and unpaid interest.